Adaptive Pet Study



Status:Completed
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/24/2018
Start Date:January 2012
End Date:September 2016

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

F Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for the Delivery of Adaptive Radiation Therapy

The purpose of this study is to determine the benefit of using positron emission tomography
(PET) in addition to the standard (computed tomography) CT to plan radiation therapy for
cancer treatment. The information from the PET-CT may allow the investigators to change the
radiation plan or the delivery of the radiation to the tumor/tumor site such as the total
dose of radiation or the size of the area to receive further radiation. Presently the use of
PET scans to adjust radiation therapy during radiation treatment is not standard of care and
is being investigated in this study.


Inclusion Criteria:

- Pathologically (histologically or cytologically) proven diagnosis of carcinoma

- Patients with local or regional nodal disease are eligible.

- Zubrod Performance Status 0, 1, or 2.

- Age ≥ 18

- Negative serum pregnancy test for women of child bearing potential

- Patient must sign study-specific informed consent prior to study entry.

Exclusion Criteria:

- No gross disease visible on imaging at the start of radiotherapy

- Contraindication to PET

- Complete response by PET achieved with pre-radiation therapy treatment (surgery or
chemotherapy)

- Breast feeding
We found this trial at
1
site
Duke Univ Med Ctr
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials